Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors

BACKGROUND: Immune checkpoint inhibitors (anti-CTLA-4, anti-PD-1, or the combination) enhance anti-tumor immune responses, yielding durable clinical benefit in several cancer types, including melanoma. However, a subset of patients experience immune-related adverse events (irAEs), which can be sever...

Descripción completa

Detalles Bibliográficos
Autores principales: Gowen, Michael F., Giles, Keith M., Simpson, Danny, Tchack, Jeremy, Zhou, Hua, Moran, Una, Dawood, Zarmeena, Pavlick, Anna C., Hu, Shaohui, Wilson, Melissa A., Zhong, Hua, Krogsgaard, Michelle, Kirchhoff, Tomas, Osman, Iman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5880088/
https://www.ncbi.nlm.nih.gov/pubmed/29606147
http://dx.doi.org/10.1186/s12967-018-1452-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5880088/
https://www.ncbi.nlm.nih.gov/pubmed/29606147
http://dx.doi.org/10.1186/s12967-018-1452-4

Ejemplares similares